DE602006002495D1 - Verfahren zur herstellung von optisch aktiven derivaten von 2-(2-pyridylmethylsulfinyl)benzimidazol über einen einschlusskomplex mit 1,1'-binaphthalin-2, 2'-diol - Google Patents

Verfahren zur herstellung von optisch aktiven derivaten von 2-(2-pyridylmethylsulfinyl)benzimidazol über einen einschlusskomplex mit 1,1'-binaphthalin-2, 2'-diol

Info

Publication number
DE602006002495D1
DE602006002495D1 DE602006002495T DE602006002495T DE602006002495D1 DE 602006002495 D1 DE602006002495 D1 DE 602006002495D1 DE 602006002495 T DE602006002495 T DE 602006002495T DE 602006002495 T DE602006002495 T DE 602006002495T DE 602006002495 D1 DE602006002495 D1 DE 602006002495D1
Authority
DE
Germany
Prior art keywords
benzimidazole
diol
optically active
inclusion complex
binaphthalin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006002495T
Other languages
English (en)
Inventor
Laura Coppi
Maimo Ramon Berenguer
Guillen Yolanda Gasanz
Ruperez Jorge Medrano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Quimica SA
Original Assignee
Esteve Quimica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Quimica SA filed Critical Esteve Quimica SA
Publication of DE602006002495D1 publication Critical patent/DE602006002495D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DE602006002495T 2005-03-03 2006-02-22 Verfahren zur herstellung von optisch aktiven derivaten von 2-(2-pyridylmethylsulfinyl)benzimidazol über einen einschlusskomplex mit 1,1'-binaphthalin-2, 2'-diol Active DE602006002495D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200500546A ES2259269B1 (es) 2005-03-03 2005-03-03 Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
PCT/EP2006/060193 WO2006094904A1 (en) 2005-03-03 2006-02-22 Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1'-binaphthalene-2, 2'diol

Publications (1)

Publication Number Publication Date
DE602006002495D1 true DE602006002495D1 (de) 2008-10-09

Family

ID=36293310

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006002495T Active DE602006002495D1 (de) 2005-03-03 2006-02-22 Verfahren zur herstellung von optisch aktiven derivaten von 2-(2-pyridylmethylsulfinyl)benzimidazol über einen einschlusskomplex mit 1,1'-binaphthalin-2, 2'-diol

Country Status (19)

Country Link
US (1) US7777044B2 (de)
EP (1) EP1858881B1 (de)
JP (1) JP5097559B2 (de)
KR (1) KR101246479B1 (de)
CN (1) CN101133049B (de)
AT (1) ATE406362T1 (de)
AU (1) AU2006222032B2 (de)
CA (1) CA2598224C (de)
CY (1) CY1108491T1 (de)
DE (1) DE602006002495D1 (de)
DK (1) DK1858881T3 (de)
ES (2) ES2259269B1 (de)
HR (1) HRP20080510T3 (de)
MX (1) MX2007010705A (de)
NO (1) NO20074978L (de)
NZ (1) NZ561214A (de)
PT (1) PT1858881E (de)
WO (1) WO2006094904A1 (de)
ZA (1) ZA200707335B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
KR100641534B1 (ko) * 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
BRPI0621832A2 (pt) 2006-07-05 2013-03-19 Lupin Ltd processo para a preparaÇço de enantiâmeros oticamente puros ou oticamente enriquecidos de compostos de sulfàxido
EP2152691B1 (de) * 2007-06-07 2011-11-23 Aurobindo Pharma Limited Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
WO2009087672A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole
EP2303868A2 (de) 2008-05-14 2011-04-06 Watson Pharma Private Limited Stabiles r(+)-lansoprazolaminsalz und verfahren zu seiner herstellung
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010058409A2 (en) 2008-11-18 2010-05-27 Hetero Research Foundation Optical purification of esomeprazole
WO2010072759A1 (en) * 2008-12-24 2010-07-01 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of esomeprazole
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
CN102887885B (zh) * 2012-09-26 2014-12-10 江苏正大丰海制药有限公司 一种埃索美拉唑钠的制备方法
CN103483407B (zh) * 2013-10-10 2015-11-18 宁夏启元药业有限公司 一种硫氰酸红霉素萃取结晶用复合溶媒及萃取结晶方法
EP2980086B1 (de) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Effizientes Verfahren zur Herstellung von Esomeprazol (S)-Binol Komplex
CZ305940B6 (cs) * 2014-10-17 2016-05-11 Vysoká škola chemicko - technologická v Praze Močovina na bázi binaftalenu pro stanovení enantiomerní čistoty chirálních sulfoxidů pomocí 1H-NMR analýzy
CZ307419B6 (cs) * 2014-10-17 2018-08-08 Vysoká škola chemicko-technologická v Praze Způsob stanovení enantiomerní čistoty chirálních sulfoxidů pomocí 1H-NMR analýzy
CN105294544B (zh) * 2015-11-30 2017-09-22 山东罗欣药业集团股份有限公司 一种高纯度匹可硫酸钠的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
CN1087739C (zh) * 1998-12-28 2002-07-17 中国科学院成都有机化学研究所 光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法
US7169793B2 (en) 2002-06-27 2007-01-30 Dr. Reddy's Laboratories Limited Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
CN1223262C (zh) * 2003-08-07 2005-10-19 广水市东晨菌业科技有限公司 天麻有性繁殖同步栽培的方法
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
ES2325336T3 (es) 2005-12-28 2009-09-01 Union Quimico-Farmaceutica, S.A. Procedimiento para la preparacion del enantiomero (s) de omeprazol.

Also Published As

Publication number Publication date
US20080167473A1 (en) 2008-07-10
AU2006222032B2 (en) 2011-03-10
DK1858881T3 (da) 2008-12-01
PT1858881E (pt) 2008-10-08
ZA200707335B (en) 2008-12-31
CA2598224C (en) 2012-08-28
WO2006094904A1 (en) 2006-09-14
NZ561214A (en) 2009-09-25
NO20074978L (no) 2007-11-23
KR101246479B1 (ko) 2013-03-21
ATE406362T1 (de) 2008-09-15
KR20070113212A (ko) 2007-11-28
MX2007010705A (es) 2007-11-08
ES2259269A1 (es) 2006-09-16
CN101133049B (zh) 2011-03-30
CY1108491T1 (el) 2014-04-09
HRP20080510T3 (en) 2008-12-31
EP1858881A1 (de) 2007-11-28
AU2006222032A1 (en) 2006-09-14
CN101133049A (zh) 2008-02-27
JP5097559B2 (ja) 2012-12-12
EP1858881B1 (de) 2008-08-27
ES2313617T3 (es) 2009-03-01
CA2598224A1 (en) 2006-09-14
ES2259269B1 (es) 2007-11-01
JP2008531641A (ja) 2008-08-14
US7777044B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
DE602006002495D1 (de) Verfahren zur herstellung von optisch aktiven derivaten von 2-(2-pyridylmethylsulfinyl)benzimidazol über einen einschlusskomplex mit 1,1'-binaphthalin-2, 2'-diol
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
MA29464B1 (fr) Methode de preparation d'acides 1,6-dihydro-6-oxo-4-pyrimidinecarboxyliques eventuellement 2-substitues
NZ593214A (en) Compounds and Processes for preparing serine protease inhibitors
WO2008005914A3 (en) Novel glucokinase activators and methods of using same
UA94449C2 (ru) Способ получения оптически активного соединения оксида хромена
ES2572148T3 (es) Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
WO2008131860A3 (de) Pyridoncarboxamide, diese enthaltende nutzpflanzenschützende mittel und verfahren zu ihrer herstellung und deren verwendung
MX2008014101A (es) Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
NO345018B1 (no) Framgangsmåte for framstilling av organofluorforbindelser i alkoholholdige løsningsmidler.
UY29457A1 (es) Compuestos novedosos de derivados de aminosulfonilo
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
AR052894A1 (es) Derivado de diazabiciclononeno
EA200901573A1 (ru) Гетероарилзамещенные тиазолы
ME00835B (me) Novi postupak za razdvajanje enentiomera (3,4-dimetoksi­ biciklo[4.2.0]okta-1,3,5-trien-7-il)nitrila i primena u sintezi ivabradina
DE602007004874D1 (de) Lösungsmittelzusammensetzung enthaltend mindestens zwei lösungsmittel, und pflanzenschutzformulierung, die diese zusammensetzung und einen wirkstoff enthält
HRP20051019A2 (en) A method for the preparation of enantiomerically pure mirtazapine
CY1110688T1 (el) Διεργασια για την παρασκευη καρβεδιλολης και εναντιομερων αυτης
UA92050C2 (ru) Энантиоселективное получение производных бензимидазола и их солей
DE602005020717D1 (de) Verfahren zur Beschichtung von nanostrukturierte Elektroden
ATE534643T1 (de) Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
ATE514702T1 (de) Verfahren zur herstellung von clopidogrel und dabei verwendete zwischenprodukte
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
ECSP056103A (es) Tratamiento de pigmentos de alto rendimiento

Legal Events

Date Code Title Description
8364 No opposition during term of opposition